 |
|
Fostering Innovation and Discovery in Biomedical Research
Thomas R. Cech, PhD
JAMA. 2005;294:1390-1393.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In today’s scientific era, molecular research has paved the way for the development of pharmaceuticals that are improving the lives of millions of patients. The discovery of the human immunodeficiency retrovirus as the causative agent of AIDS led to the development of reverse transcriptase inhibitors such as zidovudine. Monoclonal antibodies directed against tumor necrosis factor  have changed the lives of many patients with rheumatoid arthritis. Imatinib mesylate, a specific inhibitor of the bcr-abl protein kinase, has transformed the prognosis for patients with chronic myeloid leukemia; and as drug-resistant variants arise, DNA sequencing can identify the mutations responsible and provide a rational basis for further drug development.1-2 In 2004 the first angiogenesis inhibitors were approved by the US Food and Drug Administration, in one case for treatment of metastatic colorectal cancer and in another for age-related macular degeneration.3-4 There is reason for optimism that this is just . . . [Full Text of this Article]The NIH Dominates
Author Affiliation: Howard Hughes Medical Institute, Chevy Chase, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Physician-Scientist Training--Reply
Ley and Rosenberg
JAMA 2006;295:623-624.
FULL TEXT
Medical Research--State of the Science
Fontanarosa et al.
JAMA 2005;294:1424-1425.
FULL TEXT
|
